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Background: Despite a significant reduction in the number of malaria cases in Guyana and Suriname, this disease
remains a major problem in the interior of both countries, especially in areas with gold mining and logging
operations, where malaria is endemic. National malaria control programmes in these countries provide treatment to
patients with medicines that are procured and distributed through regulated processes in the public sector.
However, availability to medicines in licensed facilities (private sector) and unlicensed facilities (informal sector) is
common, posing the risk of access to and use of non-recommended treatments and/or poor quality products.
Methods: To assess the quality of circulating anti-malarial medicines, samples were purchased in the private and
informal sectors of Guyana and Suriname in 2009. The sampling sites were selected based on epidemiological data
and/or distance from health facilities. Samples were analysed for identity, content, dissolution or disintegration,
impurities, and uniformity of dosage units or weight variation according to manufacturer, pharmacopeial, or other
validated method.
Results: Quality issues were observed in 45 of 77 (58%) anti-malarial medicines sampled in Guyana of which 30
failed visual & physical inspection and 18 failed quality control tests. The proportion of monotherapy and ACT
medicines failing quality control tests was 43% (13/30) and 11% (5/47) respectively. A higher proportion of
medicines sampled from the private sector 34% (11/32) failed quality control tests versus 16% (7/45) in the informal
sector. In Suriname, 58 medicines were sampled, of which 50 (86%) were ArtecomW, the fixed-dose combination of
piperaquine-dihydroartemisinin-trimethoprim co-blistered with a primaquine phosphate tablet. All Artecom samples
were found to lack a label claim for primaquine, thus failing visual and physical inspection.
Conclusions: The findings of the studies in both countries point to significant problems with the quality of anti-
malarial medicines available in private and informal sector facilities as well as the availability of therapy not
compliant with national treatment guidelines. They also stress the need to strengthen regulatory control efforts on
the availability of anti-malarial medicines in these sectors and in endemic areas.Background
Malaria transmission in the Amazon Basin of South Amer-
ica has fallen dramatically in the past 10 years. The malaria
control programmes in Suriname and Guyana have made
tremendous strides in reducing malaria transmission, espe-
cially in Suriname where the implementation of various
strategies has lead to pre-elimination [1,2]. Suriname has
had a 92% reduction in the transmission of Plasmodium* Correspondence: le@usp.org
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Guyana has experienced a reduction in reported malaria
cases from 2005 to 2007 [3]. However, malaria continues to
be a major public health problem in the interior of Guyana
and Suriname, where gold mining and logging are the
major occupations and access to public sector facilities is
minimal due to a limited road system and rugged terrain.
In these areas, febrile illnesses are usually assumed to be
malaria and treatment is first sought in private sector facil-
ities – licensed pharmacies, wholesalers and distributors
and informal sector facilities – unlicensed shops and conve-
niences stores [3]. For gold-miners, who are paid by thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pected malarial illness are secondary to rapid relief of symp-
toms and an early return to work since absenteeism due to
illness can severely impact their wages. The cost of these
medicines is not a major consideration for most gold
miners, and local shop owners usually carry a wide range of
anti-malarials from a variety of sources, including more ex-
pensive artemisinin monotherapy and artemisinin-based
combination therapy (ACT) [4].
Cases of counterfeit and substandard essential medi-
cines have been reported in South America [5,6]. How-
ever, little is known about the quality of anti-malarials in
the private and informal sectors because most malaria
medicine-quality monitoring (MQM) activities in the re-
gion have focused on the public sector [7]. Therefore,
these studies were performed in Guyana and Suriname,
where private and informal sectors are prevalent, to as-
sess the quality of anti-malarial medicines. The goal was
to determine the quality of the collected anti-malarial
medicines using pharmacopeial or other validated meth-
ods, thus providing evidence for targeted interventions.
Similar studies of anti-malarials in the private and infor-
mal sectors in Southeast Asia and Africa have shown
high frequencies of poor quality medicines [8-15].
The studies described in this report took place in the
context of the Amazon Malaria Initiative (AMI), a
seven-country regional programme established by the
United States Agency for International Development
(USAID), which was launched in 2001. The report also
contains many of the attributes recommended in the
Medicine Quality Assessment Reporting Guidelines
[MEDQUARG] developed to improve the reporting of
medicine quality data [16].
Methods
The studies consisted of four phases: (1) identification of
the sampling sites, in consultation with health profes-
sionals in the country; (2) training of personnel in sam-
pling and data recording; (3) collection of medicine
samples; and, (4) sample analysis (quality control testing)
and review of results. The testing of the samples was
carried out at the United States Pharmacopeia (USP) la-
boratory in Rockville, Maryland, and at a collaborating
laboratory, the Centro Nacional de Control de Calidad,
Instituto Nacional de Salud, Ministerio de Salud Pública,
Peru. Both laboratories operate in compliance with inter-
nationally recognized standards and have ISO: IEC
17025:2005 accreditation.
Selection of sampling sites
The sites for medicine sampling were selected in consult-
ation with national malaria control programme authorities
and regional Ministry of Health personnel. Selection was
based on the level of mining or logging activity in the area,consultation with regional health personnel, malaria
prevalence, population density, and/or distance from pub-
lic health clinics located within a region.
In Guyana the study focused on six of its 10 regions:
Barima-Waini (Region 1), Pomeroon-Supenaam (Region
2), Demerara-Mahaica (Region 4), Cuyuni-Mazaruni
(Region 7), Potara-Siparuni (Region 8) and Upper
Demerara-Berbice (Region 10) (Figure 1). Regions 1, 7
and 8 were selected because of their high malaria preva-
lence and the fact that they are home to numerous gold-
mining operations, an activity that creates the environ-
ment for the breeding of the vector and exposes workers
to infection. Regions 2, 4 and 10 were “source” regions,
selected because miners, shopkeepers, and others often
purchase anti-malarial medicines in the urban centres of
these regions, before travelling to the more remote mal-
arious areas.
In Suriname, the sampling scheme essentially followed
the supply lines for the mining camps, which are based
around the river system - the primary route of travel in
these isolated regions (Figure 2). These areas include the
Lawa River, Brokopondo Lake, Saramacca River, Maro-
wijine River, and the area around the Tapanahony River
in the eastern part of the country. Samples were also
collected from the capital city of Paramaribo.
Training and sampling
Local workers were trained utilizing standard sampling
guidelines and implemented overt and mystery shopping
techniques to collect samples [17]. Collectors were
instructed to purchase the medicines in their original
packaging; for medicines sold in bulk where that was
not possible, they were asked to gather as much infor-
mation as possible from the vendor regarding the name
of the medicine, strength, expiry date, name of the
manufacturer, and country of origin. All the relevant in-
formation was recorded on a standardized form as soon
as possible after leaving the point of sale and before per-
forming the next purchase.
The objective was to collect between 60 and 100 sam-
ples per country and a minimum of five units per sample
(a unit is the individual tablet or capsule in a sample).
All samples collected were handled to ensure sample in-
tegrity and avoid contamination. In Guyana, the data
collectors were instructed to sample as many different
anti-malarial medicines as possible at each site with pri-
ority given to artemisinin monotherapy or combinations.
On the other hand in Suriname, most of the samples
were of one particular ACT, Artecom, which was the
most prevalent medicine identified.
Quality control testing
All medicines underwent visual and physical inspection
prior to quality control testing. A QC test failure was
Figure 1 Map of sampling sites in Guyana.
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tification, content, dissolution and etc.) for which it was
evaluated. Overall failures were based on QC test and/or
visual & physical inspection failures. A sample failing both
a QC test and visual & physical inspection was considered
as a single failure.
The quality of amodiaquine (AQ), primaquine (P), quin-
ine (Q) and chloroquine (C) solid dosage forms was evalu-
ated according to their individual monographs in the USP-
NF [18]. Halofantrine and artesunate tablets were analysed
following monographs in the British and International
Pharmacopoeias respectively [19,20]. The quality of meflo-
quine tablets was determined following the USP non-U.S.
monograph [21]. ACT was evaluated by pharmacopeial,
journal published, and manufacturers’ validated methods
and pharmacopeial specifications for single medicines after
they were determined to be suitable for use. The methods
used in ACT analysis are given in Table 1. The dihydroarte-
misinin (DHA) content in Artecom and Artemos-40 was
determined using a validated procedure provided by the
Vietnamese National Institute of Drug Quality. The proce-
dures to determine the content of sulphamethoxypyrazine(SMP) and pyrimethamine (PM) in Co-Arinate were
obtained from the manufacturer.
Due to limited sample availability, not all specified tests
could be conducted on a sample therefore the type of tests
performed depended on the number of units collected. In
cases where the number of sample units was limited, iden-
tification (ID) and content/assay tests were given priority,
followed by disintegration or dissolution testing. The
Artecom and Artemos-40 samples were evaluated for dis-
integration since no suitable dissolution test was found.
The Co-Arinate samples were evaluated for the dissol-
ution of sulphamethoxypyrazine and pyrimethamine.
Artemos-Plus samples were the only ACT evaluated for
impurity content as these were the only products for
which suitable impurity procedures were available. In
addition, uniformity of dosage units (UDU) or weight vari-
ation (WV) was performed on all samples. There were six
expired medicine samples (four were expired at time of
sample collection and two expired before analysis): quality
control analysis was limited to identification in this case,
except for one sample, which was also evaluated for con-
tent. Due to the labour-intensive nature involved in the
Figure 2 Map of sampling sites in Suriname.
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Suriname was selected for evaluation. Expired medicines
were excluded and not more than two samples with the
same lot number but collected at different sites were
analysed.
Results
Distribution, prevalence, source, origin and packaging
A total of 77 anti-malarial medicine samples collected
between June and August 2009 from six regions of
Guyana were analysed for quality. Of the 77 samples, 46
(60%) came from three “malaria endemic” regions (1, 7
and 8), and 31 (40%) from “source” regions (2, 4 and
10). The samples had been collected from 45 premises,
16 of which were private sector facilities and 29 were in-
formal sector facilities. The majority of the samples
(58%) were collected from the informal sector while 48%
were obtained from facilities in the private sector.
More than half of the samples 47/77 (61%) were ACT,
and 30/77 (39%) were monotherapy, that also included
non-artemisinin derivatives, such as chloroquine and
primaquine, the nationally recommended treatments for
Plasmodium vivax in Suriname and Guyana. Dihydroarte-
misinin was the dominant artemisinin derivative found
among ACT samples while the fixed dose combination of
artesunate, sulphamethoxypyrazine and pyrimethaminewas the second most widely encountered. Only one sam-
ple contained artemether. No samples of the fixed dose
combination of lumefantrine – artemether, the nationally
recommended treatment for P. falciparum were collected
in either country. It is noteworthy that artesunate was also
found among the monotherapy samples: two of the three
artesunate samples came from a private pharmacy, the
other an illegal vendor.
Based on the sampling results, the informal sector sells
primarily ACT. Only 24% of the samples collected in
this sector were monotherapy. This is in sharp contrast
to the private sector where 59% (19/32) of the samples
were monotherapy. Two ACT in particular, Artecom
and Co-Arinate, were found to be very popular in the in-
formal sector; though they were also present in a lesser
extent in private sector pharmacies. Together Artecom
(26 samples, 20 in the informal and 6 in the private sec-
tor) and Co-Arinate (19 samples, 14 in the informal and
5 in the private sector) represented 59% of all samples
collected.
Most of the samples collected (63/77 or 82%) were
obtained in their original individual container and included
the package inserts. The other 14 samples (seven private
sector and seven informal sector samples) were obtained
from bulk containers, including unlabelled ones. Storage
conditions in the informal sector were often unsatisfactory,
Table 1 ACT analytical methods
ACT Active Pharmaceutical Ingredients in ACT
Artecom • dihydroartemisinin (DHA)
• piperaquine (PPQ) [22]
• trimethoprim (TMP) [18]
• primaquine (P) [18]
Artemos-40 • dihydroartemisinin (DHA)
• piperaquine (PPQ) [22]
• trimethoprim (TMP) [18]
Co-Arinate • artesunate (AS) [20]
• sulphamethoxypyrazine (SMP)
• pyrimethamine (PM)
Artemos-Plus • artemether (A) [23]
• lumefantrine (L) [24]
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very high ambient temperatures. In four cases, two in the
private and two in the informal sectors, medicines were
stored in unlabelled containers and no information could
be obtained regarding the source or expiry date. Sampled
medicines were labeled as manufactured in China (44%),
Italy (24%), Cyprus (10%), Guyana (6%), India (5%), Paki-
stan (3%) and Switzerland (3%); the manufacturer was un-
known for 5% of the medicines.
In Suriname, a total of 57 samples were collected from
informal sector facilities in the Marowijne, Paramaribo
and Sipaliwini districts with the majority collected in Sipa-










Artemos-Plus 1 0 0 0
Co-Arinate 19 0 0 0
Artemos-40 1 0 0 1
Artecom 26 26 0 3
Amodiaquine 5 0 0 0
Artesunate 3 1 0 2
Chloroquine 4 1 0 2
Halofantrine 2 0 0 0
Mefloquine 7 0 1 0
Primaquine 4 1 0 2
Quinine 5 1 1 0
Total 77 30 (39%) 2 10
1 Some medicines failed more than one QC test.
2Medicines failing visual & physical inspection or QC test. A medicine failing both w
A dash “-“ indicates the test was not performed.These samples were from the same manufacturer as those
sampled in Guyana; they comprised a total of eight differ-
ent lots, three of which were the same as those found in
Guyana.Visual & physical inspection and quality control test
results
Approximately 58% (45/77) of the anti-malarial medi-
cines sampled in Guyana were found to be of poor qual-
ity (Table 2), meaning the medicine failed one of the
quality control tests and/or visual and physical inspec-
tion. The 45 failed samples represented three of the four
presentations of ACT and five of the seven different
monotherapy. The majority of the samples tested failed
the test for content. Among monotherapy, nine of the
30 samples collected failed the test for dissolution while
samples of quinine (Q) and mefloquine (M) tablets were
found to not contain API. All of the artesunate tablet
medicines were found to be of poor quality, two samples
failed test for content, dissolution and impurities with
the other sample failing visual & physical inspection.
Similar quality issues were also found for two chloro-
quine samples. In both cases the samples were from the
same manufacturer and batch, indicative of manufactur-
ing issues.
Among the 18 medicines failing quality control tests,
five (28%) were ACT, including three Artecom samples.
While three of 26 Artecom samples failed the content test
for one of the FDC constituents, DHA, a greater problem






olution Disintegration Impurity UDU/WV
- - 1 0 1 1 (100)
0 0 - 0 0 0 (0)
- 0 - 1 1 1 (100)
- 0 - 1 3 26 (100)
0 - 0 0 0 0 (0)
2 - 2 1 2 3(100)
2 - - 2 2 3 (75)
- - - 0 0 0 (0)
4 - 0 0 5 5 (71)
- - - 0 2 3 (75)
1 - 0 0 2 3 (60)
9 0 3 5 18 (23%) 45 (58)
as considered as a single failure.
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base however, the package label did not provide informa-
tion regarding the strength of the primaquine tablet
resulting in a failure by visual and physical inspection.
The failure rates were similar in the malaria endemic
Regions 1, 7 and 8 (24%) and the non-endemic “source”
regions 2, 4 and 10 (23%). The highest proportion of fail-
ures, 30%, was found in Region 4 but, Regions 7 and 8.
also stood out with 29% of samples failing quality con-
trol testing (Table 3). The test results also show a differ-
ence in medicine quality risk between buying from the
private sector, where 34% (11/32) of samples failed, and
buying from the informal sector, where there was a fail-
ure rate of 16% (7/45).
The quality control test results for Artecom samples
from Suriname mirrored the test results from Guyana.
All Artecom samples lacked primaquine dosage strength
information on the packaging, a labeling violation by
most MRAs. As in the case of the Artecom samples
from Guyana, compliance to a label claim could not be
assessed for the Suriname samples.
Discussion
The itinerant behaviour of people inhabiting the hinter-
land regions (indigenous peoples, miners, and loggers)
and the great distances between camps and officially sanc-
tioned public health care facilities are conducive to self-
medication and purchase from alternative sources. In
these malaria endemic areas, there is a lack of health care
professionals correctly dispensing medicines, even in pri-
vate pharmacies. Anti-malarials are often dispensed by a
non-pharmacist in the pharmacies, without requiring a
prescription. As for informal sector vendors, the incentive
to sell anti-malarials from under the counter is high. The
commercial value of the current combination medicines
containing artemisinin derivatives is significant and the
demand is there.Table 3 Quality control test results by region, sector and anti
Region Failures Failures by Se
Private
1 18% (4/22) -*
7 29% (5/17) 3
8 29% (2/7) 1
Total1 24% (11/46) 4
2 15% (2/13) 2
4 30% (3/10) 3
10 25% (2/8) 2
Total2 23% (7/31) 7
Total 23% (18/77) 34% (11/32)
*No samples were collected in this sector in the indicated region.
1Totals for malaria endemic regions 1,7 and 8.
2Totals for “source” regions 2, 4 and 10.Many of the anti-malarial medicines sampled from the
private and informal sectors were not registered nor
were they part of the national standard treatment guide-
lines. Medicines from both sectors, and across the varied
regions, were of poor quality and several were found to
be expired. Artemisinin monotherapy were also avail-
able, yet WHO guidelines do not recommend their use
as treatment for uncomplicated P. falciparum malaria.
In the context of quality problems, of particular note
is the case of the ACT, Artecom, which was not regis-
tered in either Guyana or Suriname. Based on vendors’
accounts and sampling results, it was the most popular
anti-malarial in the informal sector in both countries.
Interestingly, the same lot number was found for sam-
ples collected in both Guyana and Suriname, suggesting
the possibility of a common supply source and/or illegal
cross-border commerce of malaria medicines. Also, the
packaging did not include dosage strength information
for the content of primaquine, making it impossible to
assess content and violates labeling requirements estab-
lished in pharmacopeias and by most MRAs. In addition,
the lack of primaquine content poses a safety concern to
glucose-6-phosphate dehydrogenase (G6PD) deficient
individuals receiving malaria treatment [25].
Samples of quinine and mefloquine tablets collected
were found to not contain API, which may raise the
issue of counterfeit medicines. However, according to le-
gislation in Guyana, when a medicine contains no active
ingredient it is considered as substandard unless there is
other incriminating evidence that proves the drug is
counterfeit. Additional incriminating evidence (i.e., sus-
picious packaging) was not found to make such a claim.
In addition, the medicines were both sampled from bulk
containers, which brought into play the potential for
human error.
Non-compliance to GMP in the production of malaria
medicines has been shown to be a problem among-malarial class - Guyana










16% (7/45) 11% (5/47) 43% (13/30)
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results indicate quality problems were observed among
locally manufactured and foreign products. Both artesu-
nate (foreign product) and chloroquine (domestic prod-
uct) failed tests for content, dissolution and uniformity
of dosage units, quality attributes that are sensitive to
variations in manufacturing. Although regulatory au-
thorities are more capable of addressing problems with
local manufactures, most malaria medicines are pro-
cured from abroad. Limited human and financial
resources hinder their abilities to conduct inspections of
international manufacturers.
The test results obtained were shared with regulatory
authorities in both countries. It is hoped that the find-
ings from this and other published studies will help pro-
vide a basis for targeted interventions. If it is not feasible
for the public sector to expand services, it is recom-
mended that health authorities increase inspections,
training and monitoring of staff in private sector phar-
macies to improve dispensing practices. Furthermore, if
it would prove unfeasible to promptly eliminate sales of
anti-malarials in the informal sector, the following
approaches could be considered: 1) expand programmes,
such as the active-case detection component of the
“Looking for Gold Finding Malaria” programme in
Suriname sponsored by the Global Fund to Fight Aids,
Tuberculosis and Malaria; 2) include selected vending
sites or stores in a parallel training, monitoring and in-
spection programme in order to improve knowledge and
dispensing of anti-malarials (cf. the model successfully
introduced in Tanzania) [15]. Public awareness cam-
paigns about the importance of good quality medicines
and the risk of purchasing from the informal sector can
also have an impact [27,28]. The aim is not only to pro-
tect patients from harm, but also to protect currently ef-
fective treatments and prevent the development of drug
resistance.
Conclusions
The Guyana results illustrate the persistent problem of
poor quality medicines and other aspects of irrational
use of anti-malarial medicines in countries, especially if
the malaria-endemic regions are remote or difficult to
access. As illustrated by the Guyana test results in par-
ticular, there is a greater chance of buying non-
registered and/or poor quality products in private estab-
lishments than in informal ones.
Findings from these studies are similar to those that
investigated the quality of medicines in the private and
informal sectors in Africa and Southeast Asia, where
there was also high incidence of poor quality anti-
malarials [28-30]. Coupled with the ease with which the
artemisinin-based products can be acquired and the
availability of clinically inappropriate artemisinin-basedmonotherapy, these are a major cause for worry. To-
gether, they not only risk patient safety but also present
serious implications for the development of drug-
resistant strains of the Plasmodium parasite. A novel
treatment is not foreseeable in the near future, thus pla-
cing malaria treatment at risk globally.
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